These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 28489727

  • 21. 6-methylmercaptopurine-induced leukocytopenia during thiopurine therapy in inflammatory bowel disease patients.
    Meijer B, Kreijne JE, van Moorsel SAW, Derijks LJJ, Bouma G, Mulder CJJ, Wong DR, van der Woude CJ, van Bodegraven AA, de Boer NKH.
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1183-1190. PubMed ID: 27859568
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Novel assay to improve therapeutic drug monitoring of thiopurines in inflammatory bowel disease.
    Vikingsson S, Andersson D, Almer S, Peterson C, Hindorf U.
    J Crohns Colitis; 2014 Dec; 8(12):1702-9. PubMed ID: 25239576
    [Abstract] [Full Text] [Related]

  • 24. Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
    Hindorf U, Lyrenäs E, Nilsson A, Schmiegelow K.
    Scand J Gastroenterol; 2004 Nov; 39(11):1105-12. PubMed ID: 15545169
    [Abstract] [Full Text] [Related]

  • 25. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
    Wong DR, Coenen MJ, Vermeulen SH, Derijks LJ, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM, TOPIC recruitment team.
    J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
    [Abstract] [Full Text] [Related]

  • 26. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB, Barclay ML.
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [Abstract] [Full Text] [Related]

  • 27. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
    Thomas CW, Lowry PW, Franklin CL, Weaver AL, Myhre GM, Mays DC, Tremaine WJ, Lipsky JJ, Sandborn WJ.
    Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
    [Abstract] [Full Text] [Related]

  • 28. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML.
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Analytical Pitfalls of Therapeutic Drug Monitoring of Thiopurines in Patients With Inflammatory Bowel Disease.
    Simsek M, Meijer B, Mulder CJJ, van Bodegraven AA, de Boer NKH.
    Ther Drug Monit; 2017 Dec; 39(6):584-588. PubMed ID: 29040228
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease.
    Sánchez Rodríguez E, Ríos León R, Mesonero Gismero F, Albillos A, Lopez-Sanroman A.
    Gastroenterol Hepatol; 2018 Dec; 41(10):629-635. PubMed ID: 30107940
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S.
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [Abstract] [Full Text] [Related]

  • 37. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
    Kwan LY, Devlin SM, Mirocha JM, Papadakis KA.
    Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
    [Abstract] [Full Text] [Related]

  • 38. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides.
    Duley JA, Florin TH.
    Ther Drug Monit; 2005 Oct; 27(5):647-54. PubMed ID: 16175140
    [Abstract] [Full Text] [Related]

  • 39. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides.
    Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML.
    Eur J Gastroenterol Hepatol; 2008 Dec; 20(12):1238-42. PubMed ID: 18989148
    [Abstract] [Full Text] [Related]

  • 40. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.
    Jharap B, de Boer N, Vos R, Smid K, Zwiers A, Peters G, Mulder C, Wilhelm A, van Bodegraven A.
    Br J Pharmacol; 2011 Jun; 163(4):722-31. PubMed ID: 21323897
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.